Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Guangbi, Yao"'
Autor:
Guangbi, Yao, Baoen, Wang
Publikováno v:
Chinese Journal of Digestive Diseases. Nov2000, Vol. 1 Issue 1, p29. 6p.
Autor:
Daozheng Xu, Bao-En Wang, Guangbi Yao, Laurie MacDonald, Xia-Qiu Zhou, Jessica Liu, Dong Xu, Hong Ren
Publikováno v:
Hepatology International. 1:373-381
This randomized, double-blind, placebo-controlled study was undertaken to evaluate the efficacy and safety of entecavir in Chinese patients with lamivudine-refractory chronic hepatitis B.One hundred forty-five lamivudine-refractory patients with chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db48e66a46ceadb16da611d7dbdce2ae
https://doi.org/10.1007/s12072-007-9016-3
https://doi.org/10.1007/s12072-007-9016-3
Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China
Autor:
Guangbi Yao
Publikováno v:
Journal of Antimicrobial Chemotherapy. 60:201-205
Infection with the hepatitis B virus (HBV) can result in chronic hepatitis B (CHB) in many patients. Patients with CHB require regular screening and monitoring to facilitate disease surveillance and to determine if/when treatment is indicated. The cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ee0a192d23d74e605f175a5b007c7d
https://doi.org/10.1093/jac/dkm175
https://doi.org/10.1093/jac/dkm175
Autor:
Yun Fan Liaw, Seung Kew Yoon, Richard Guan, Masao Omata, Varocha Mahachai, Pham Hoang Phiet, Nancy Leung, Jose D. Sollano, Ting-Tsung Chang, Laurentius A. Lesmana, Guangbi Yao, Jidong Jia, S. M. Wasim Jafri, Stephen Locarnini, Shiv Kumar Sarin, Hua Zhuang, Dong Jin Suh
Publikováno v:
Liver International. 26:47-58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0afddf1c504ffc5b419bf3de763497b
https://doi.org/10.1111/j.1478-3231.2006.01374.x
https://doi.org/10.1111/j.1478-3231.2006.01374.x
Publikováno v:
Intervirology. 44:43-47
Objective: Hepatitis B virus (HBV) genotype distribution is still unclear in China, where a high prevalence of HBV infection exists, although it is well known that HBV can be classified into six genotypes based on intergroup divergence. The aim of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9b32fb3a262c8c797a5cc8b92ca3c5
https://doi.org/10.1159/000050029
https://doi.org/10.1159/000050029
Autor:
Weilun Lu, Yuming Wang, Laurie MacDonald, Chengwei Chen, Jessica Liu, Dong Xu, Daozheng Xu, Zhengrong Jiang, Guangbi Yao, Hong Ren, Deming Tan
Publikováno v:
Hepatology international. 2(1)
Chronic hepatitis B has a high prevalence (8%) in China. We compared the safety and efficacy of entecavir with that of lamivudine for the treatment of patients with chronic hepatitis B in China.A total of 519 nucleoside-naive Chinese patients with ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18710e5e640c590bfe61a276d802c01
https://pubmed.ncbi.nlm.nih.gov/19669331
https://pubmed.ncbi.nlm.nih.gov/19669331
Autor:
GuangBi Yao, Beulah Ji, Keith F. Barker, Minde Zeng, Chai-Ni P. Chang, Yi-Min Mao, YaoZong Wang, Jinlin Hou, Hao Wang
Publikováno v:
Hepatology (Baltimore, Md.). 44(1)
Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a487f75ad03c45c41a9704269c3d4b
https://pubmed.ncbi.nlm.nih.gov/16799983
https://pubmed.ncbi.nlm.nih.gov/16799983
Publikováno v:
Chinese medical journal. 115(12)
To evaluate the long-term efficacy and safety of lamivudine therapy for the treatment of chronic hepatitis B and the clinical influence of emergence of tyrosine methionine aspartic acid (YMDD) motif mutation of hepatitis B virus (HBV).This multicente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::80ca24c781b2a38858cdca9fcd09d75f
https://pubmed.ncbi.nlm.nih.gov/12622930
https://pubmed.ncbi.nlm.nih.gov/12622930
Autor:
Guangbi, Yao
Publikováno v:
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 10(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ff66edcf1c70f987fa0f166a292e782e
https://pubmed.ncbi.nlm.nih.gov/12392604
https://pubmed.ncbi.nlm.nih.gov/12392604
Publikováno v:
Zhonghua yi xue za zhi. 82(14)
To evaluate the efficacy and safety of bicyclum, a China made new hepatocyte protecting agent, in the treatment of chronic hepatitis C (CHC).Thirty-nine CHC patients matched demographically and clinically were randomized into two groups: bicyclum gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3050b1c4dbd53dbd40075cd5bd6e67c
https://pubmed.ncbi.nlm.nih.gov/12181088
https://pubmed.ncbi.nlm.nih.gov/12181088